Dr. Han C. Phan, Founder and CEORare Disease Research was established to help sponsors execute rare disease trials more efficiently. With an independent site network that specializes in rare diseases, it helps accelerate study start-up while expanding patient access to investigational therapies. The model has proven effective for all stakeholders. Over the last nine years, the organization has completed more than 50 clinical trials and contributed to five FDA approvals, without compromising quality, safety or scientific rigor.
“Our advantage is that we start the study fairly quickly, with a fast turnaround time for budget and contract,” says Dr. Han C. Phan, founder and CEO.
For sponsors, this provides an alternative to the operational complexities and delays associated with large institutions. Rare Disease Research enables them to advance studies through a network designed specifically for the unique demands of that research.
Patients benefit just as meaningfully. Underpinning Rare Disease Research's operational model is a clear purpose. Many patients living with rare diseases have limited or no approved treatment options, making clinical trials a critical pathway to potential new therapies. The organization was built on the belief that faster, more accessible research serves a greater goal by giving more patients the opportunity to participate in studies that may offer hope while advancing the development of future treatments.
The idea to establish Rare Disease Research emerged from Dr. Phan’s personal experience while working at an academic center. He recognized that sponsors needed a more responsive research partner capable of navigating the complexities of rare disease studies while expanding access to clinical trials for patients who often have few or no treatment options.
Accelerating Study Start-Up Without Compromising Quality
Rare Disease Research’s highlight is its ability to execute multiple processes simultaneously. Budgeting, contracting, regulatory preparation, site qualification and patient pre-screening begin in parallel, significantly reducing start-up timelines. By utilizing a central Institutional Review Board (IRB) alongside in-house contracting and budgeting teams, it eliminates numerous bottlenecks that commonly delay study activation.
This approach allows studies to be initiated in as little as one month, with most studies launched within two to three months.
Our advantage is that we start the study fairly quickly, with a fast turnaround time for budget and contract.
Maintaining quality standards is Rare Disease Research’s hallmark. Close communication with sponsors, particularly during the early phases of enrollment, helps minimize protocol deviations and ensures that studies progress efficiently while preserving data quality.
With rare disease clinical trials often conducted on smaller patient populations, every data point becomes critical, making accuracy, transparency and auditability essential to successful study execution.
A Patient-First Research Infrastructure
Rare disease patients frequently face challenges that extend beyond their diagnoses. Many live with mobility impairments, chronic co-morbidities, progressive neurological conditions or dependence on caregivers and specialized medical equipment. For these individuals, participation in a clinical trial often involves significant physical, financial and logistical burdens.
Rare Disease Research encountered this reality early in its development. Even today, 70 to 80 percent of patients visiting its Atlanta headquarters travel by air to participate in studies due to limited access to specialized clinical trial sites elsewhere. For those managing muscular disorders, neurological conditions or severe physical limitations, the travel itself can be a substantial health risk.
To address this challenge, Rare Disease Research built its growth strategy around accessibility rather than geography alone.
It currently operates in three locations in addition to Atlanta, in North Carolina, Florida and New Jersey. Its long-term vision is to establish 10 to 12 locations nationwide, creating a network capable of placing approximately 80 to 85 percent of the U.S. population within driving distance of a study site.
For many rare disease patients, reducing travel from a cross-country flight to a manageable two- or three-hour drive can significantly improve participation opportunities while reducing physical strain and safety risks.
The same philosophy informs its approach to decentralized clinical research.
One of Rare Disease Research's most significant successes involved a decentralized study serving an exceptionally fragile patient population. The patients required ventilators, feeding equipment and extensive caregiver support, making travel to traditional research sites highly challenging. Rather than expecting participants to adapt to conventional trial structures, the company redesigned the study around their needs.
Working closely with the sponsor, it established a fully decentralized model in which physicians, nurses and study personnel conducted visits directly in patients' homes. The study was activated within 28 days and successfully enrolled six rare disease patients who otherwise would have faced substantial barriers to participation. Every participant completed the study, generating promising data that the sponsor intends to submit for FDA review.
“A lot of these patients are not seen commonly, and because we made it a remote study, patients did not have to leave their homes,” says Dr. Phan.
For many patients with rare diseases, Rare Disease Research’s approach offers access to promising investigational therapies that may not become widely available for years, providing an important source of hope while advancing clinical research.
That commitment is reflected in the experiences of the families it serves. As one parent shared, “Enrolling in a clinical trial provided our daughter with access to a life-changing investigational therapy that wasn’t approved by the FDA until years later.”
Consistency, Compassion and Scientific Rigor
As Rare Disease Research expands its footprint, maintaining consistency across locations remains a strategic priority.
It has developed a standardized operational framework that enables every site within the network to follow the same procedures, training methodologies and study execution protocols. Whether a sponsor activates one site or multiple locations, the objective is to ensure every site follows the same SOPs, training standards, protocol requirements and data collection processes while maintaining patient safety and regulatory compliance.
-
For a lot of patients, these investigational therapies are their only hope to get some kind of treatment.
When challenges emerge at one location, teams collaborate to identify successful practices from other sites and rapidly implement solutions. This approach strengthens study performance and ensures a consistent experience for sponsors and patients alike.
Rare Disease Research also recognizes the importance of the human dimension of clinical research. Its multidisciplinary team structure includes principal investigators, nurse practitioners, research assistants and support personnel who work collaboratively across studies. Clearly defined responsibilities allow teams to coordinate patient visits, oversee safety monitoring, manage regulatory requirements and maintain continuous communication with sponsors and families.
Distinguishing it is the culture behind these processes.
Many rare disease patients enter clinical trials after exhausting available treatment options. The team recognizes that reality and approaches each study with a level of empathy that extends beyond traditional research execution.
“For a lot of patients, these investigational therapies are their only hope to get some kind of treatment,” adds Dr. Phan.
Compassion is integrated into the operational framework itself. Effective communication supports protocol adherence. Strong patient relationships improve engagement and retention. Personalized support enhances both patient experience and study execution.
Shaping the Future of Rare Disease Clinical Research
By demonstrating that rare disease clinical trials can be launched faster, conducted closer to patients and executed with exceptional scientific rigor outside traditional academic systems, Rare Disease Research has redefined what modern rare disease research looks like.
As the rare disease landscape evolves, the need for specialized and patient-focused research partners continues to grow. Rare Disease Research demonstrates that innovation depends as much on execution, accessibility and operational agility as it does on therapeutic discovery.
Its ability to accelerate study start-up, expand patient access and execute complex rare disease studies through both traditional and decentralized models has earned Rare Disease Research the recognition of Rare Disease Clinical Trials Company of the Year 2026.
Choosing Rare Disease Trial Partners that Deliver Speed without Compromising Quality
Rare disease clinical trials test more than a therapy; they test whether a research model can reach people whose geography, mobility limits and complex conditions make conventional study design fragile. For sponsors, the central question is no longer whether a site has clinical competence alone. It is whether the site can activate quickly, protect data quality, sustain enrollment and reduce participation burden without weakening protocol discipline.
The pressure is most visible at start-up. Delays in contracting, budgeting, regulatory review and site readiness can drain momentum from programs that already face small patient pools. A suitable partner should compress these early steps through coordinated internal work rather than sequential handoffs that leave one team waiting for another. Speed has value only when it is paired with careful feasibility review, clear sponsor communication and early patient identification, because a rare disease study cannot afford a fast start that produces avoidable deviations after enrollment begins.
"Rare Disease Research offers a focused, practical and sponsor-ready fit for executives selecting a rare disease trial partner."
Precision during conduct matters just as much. Rare disease programs often depend on limited cohorts, which makes each visit, assessment and data entry equally important. Executives should look for teams that treat protocol interpretation as a shared discipline across investigators, nurses, coordinators and support staff. Consistent procedures across sites, routine sponsor contact during early enrollment and disciplined safety monitoring are not administrative preferences; they are the conditions that protect evidence when sample sizes leave little room for error. This consistency is especially important when amendments, site-specific challenges or patient safety questions emerge during the earliest visits.
Access is the other decisive issue. Many rare disease patients live far from research centers and may have mobility, respiratory, or caregiver needs that make travel difficult. A strong research partner must make participation practical without treating convenience as a substitute for oversight. That may require a distributed site footprint, home-visit capability, remote or hybrid visit design and staff trained to support families as well as patients. The strongest programs balance sponsor timelines with the lived realities of participants, because recruitment and retention depend on trust as much as eligibility.
"The strongest programs balance sponsor timelines with the lived realities of participants, because recruitment and retention depend on trust as much as eligibility."
Facilities and therapeutic focus also need scrutiny. Rare disease trials can require investigational product handling, specimen processing, physical function testing, neurology experience and secure records management under GCP, ICH and HIPAA expectations. The right partner should bring disease-area familiarity and site infrastructure together, rather than relying on general clinical research experience to stretch into specialized protocols. It should also show that growth across locations does not dilute training, documentation or accountability.
Rare Disease Research stands out as the premier choice for sponsors that need rare disease trial execution built around speed, access and protocol consistency. It is an independent clinical research site network dedicated to rare disease studies, with locations in Georgia, North Carolina, Florida and New Jersey. The organization offers partner-facing study start-up in 30 to 60 days, facilities for investigational products, lab processing, testing and physical therapy assessment and experience across indications including Duchenne muscular dystrophy, spinal muscular atrophy, epilepsy and other neurological conditions.
Its model adds in-house budgeting and contracting, parallel regulatory work, centralized IRB use, early patient prescreening, SOP alignment across sites and decentralized study capability. For executives selecting a rare disease trial partner, Rare Disease Research offers a focused, practical and sponsor-ready fit.
...Read more
Rare Disease Clinical Trials Companies Info
Q1
What Are Rare Disease Clinical Trials Companies?
Rare Disease Clinical Trials Companies design and manage clinical studies that evaluate investigational therapies for conditions affecting relatively small patient populations. They work with pharmaceutical and biotechnology sponsors to plan studies, recruit participants, meet regulatory requirements, and collect reliable clinical data. Because many rare diseases have limited treatment options and small, geographically dispersed patient communities, these organizations play an important role in helping potential therapies progress through clinical development.
Q2
How Does Rare Disease Research Support Rare Disease Clinical Trials Companies?
Rare Disease Research shows how Rare Disease Clinical Trials Companies can strengthen clinical development through a research network dedicated exclusively to rare diseases. The organization conducts Phase I-IV clinical trials, gives eligible patients access to investigational therapies, and operates research sites in Georgia, North Carolina, Florida and New Jersey. Its multidisciplinary team works closely with sponsors and participants to maintain ethical research standards while supporting studies from enrollment through completion.
Q3
What Capabilities Should Organizations Look for in Rare Disease Clinical Trials Companies?
Organizations evaluating Rare Disease Clinical Trials Companies should look beyond basic trial management. Experience with complex study protocols, therapeutic expertise, patient recruitment strategies, regulatory compliance and consistent operations across multiple research sites all matter. Strong communication with patients and caregivers, experienced investigators and the ability to work with small, specialized patient populations can help keep studies on track and reduce delays that often affect rare disease research.
Q4
Why Is Patient Access So Important in Rare Disease Clinical Trials Companies?
Finding eligible participants is one of the biggest challenges for Rare Disease Clinical Trials Companies because many rare diseases affect only a small number of people spread across different regions. Organizations that make enrollment easier, provide clear information for patients and caregivers and maintain high ethical standards can improve participation in clinical research. Better access not only supports clinical studies but also gives eligible patients the opportunity to receive investigational therapies that may otherwise be unavailable.
Q5
What Makes Rare Disease Research Different From Many Rare Disease Clinical Trials Companies?
Many organizations conduct research across a wide range of therapeutic areas, but Rare Disease Research focuses exclusively on rare disease clinical trials. Its active research portfolio includes studies involving Duchenne muscular dystrophy, spinal muscular atrophy, Angelman syndrome, Friedreich's ataxia, Prader-Willi syndrome, mitochondrial disorders and several other rare conditions. This focused approach allows the organization to build deep experience while supporting both research sponsors and patients through dedicated clinical trial programs.
Q6
How Do Rare Disease Clinical Trials Companies Contribute to Future Healthcare Advances?
Rare Disease Clinical Trials Companies help generate the clinical evidence needed to evaluate the safety and effectiveness of potential therapies before they reach regulatory review. They support sponsors through the demands of complex studies, contribute to a better understanding of rare diseases and expand opportunities for future treatment development. As research continues to advance, organizations with specialized experience in rare disease clinical trials will remain an important part of bringing new treatment options closer to patients with limited therapeutic choices.
